Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: Safety and exploratory efficacy results from a phase II, randomised, parallel-group study

#4575

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for the treatment of carcinoid syndrome (CS).

Aim(s): This open-label, multicentre, dose-ranging study examined the safety, tolerability, pharmacokinetics, and exploratory efficacy of paltusotine.

Materials and methods: Eligible patients had documented grade I or II NETs with CS. Patients who were untreated and actively symptomatic (average of ≥4 bowel movements [BMs] per day or >2 flushing episodes per day in ≥2 days over 2-week period) and patients with symptom control on somatostatin receptor ligands (SRLs) who demonstrated symptom worsening after SRL washout were randomised to once-daily paltusotine 40 mg or 80 mg for 8 weeks.

Conference:

Presenting Author: Hajac L

Authors: Hajac L, Chauhan A, Mohamed A, Usiskin K, Mui C,

Keywords: paltusotine, phase 2 trial, somatostatin receptor agonist, safety, carcinoid syndrome,